NL8004585A - Werkwijze voor het bereiden van gekeratiniseerde, vaste, farmaceutische eenheidsdoseringsvormen en de aldus verkregen eenheidsdoseringsvormen. - Google Patents
Werkwijze voor het bereiden van gekeratiniseerde, vaste, farmaceutische eenheidsdoseringsvormen en de aldus verkregen eenheidsdoseringsvormen. Download PDFInfo
- Publication number
- NL8004585A NL8004585A NL8004585A NL8004585A NL8004585A NL 8004585 A NL8004585 A NL 8004585A NL 8004585 A NL8004585 A NL 8004585A NL 8004585 A NL8004585 A NL 8004585A NL 8004585 A NL8004585 A NL 8004585A
- Authority
- NL
- Netherlands
- Prior art keywords
- coating
- drug
- unit dosage
- cellulose
- salt
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 49
- 239000002552 dosage form Substances 0.000 title description 14
- 238000000576 coating method Methods 0.000 claims description 93
- 239000011248 coating agent Substances 0.000 claims description 69
- 239000003814 drug Substances 0.000 claims description 52
- 229940079593 drug Drugs 0.000 claims description 48
- 229920002678 cellulose Polymers 0.000 claims description 29
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 19
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 239000010410 layer Substances 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 239000001913 cellulose Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 9
- 239000011247 coating layer Substances 0.000 claims description 8
- 229960002508 pindolol Drugs 0.000 claims description 8
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 8
- 239000007892 solid unit dosage form Substances 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 7
- 150000003863 ammonium salts Chemical class 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- GVIRAXRGZUXHCI-UHFFFAOYSA-N 2-acetyloxycarbonylbenzoic acid Chemical compound CC(=O)OC(=O)C1=CC=CC=C1C(O)=O GVIRAXRGZUXHCI-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 239000002356 single layer Substances 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000000243 solution Substances 0.000 description 35
- 239000003826 tablet Substances 0.000 description 25
- 239000007921 spray Substances 0.000 description 15
- 210000004051 gastric juice Anatomy 0.000 description 13
- 239000002253 acid Substances 0.000 description 11
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 235000010980 cellulose Nutrition 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 240000001592 Amaranthus caudatus Species 0.000 description 6
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 6
- 239000004178 amaranth Substances 0.000 description 6
- 235000012735 amaranth Nutrition 0.000 description 6
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 6
- 229960002189 propyphenazone Drugs 0.000 description 6
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 5
- 239000011260 aqueous acid Substances 0.000 description 5
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 5
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 5
- 239000004174 erythrosine Substances 0.000 description 5
- 235000012732 erythrosine Nutrition 0.000 description 5
- 229940011411 erythrosine Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000001087 glyceryl triacetate Substances 0.000 description 4
- 235000013773 glyceryl triacetate Nutrition 0.000 description 4
- -1 hydroxypropoxy Chemical group 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 229920001059 synthetic polymer Polymers 0.000 description 4
- 229960002622 triacetin Drugs 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- 125000001137 3-hydroxypropoxy group Chemical group [H]OC([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102100028675 DNA polymerase subunit gamma-2, mitochondrial Human genes 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 101000837415 Homo sapiens DNA polymerase subunit gamma-2, mitochondrial Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- UZVHFVZFNXBMQJ-UHFFFAOYSA-N butalbital Chemical compound CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O UZVHFVZFNXBMQJ-UHFFFAOYSA-N 0.000 description 1
- 229960002546 butalbital Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7928604 | 1979-08-16 | ||
| GB7928604 | 1979-08-16 | ||
| GB7930421 | 1979-09-03 | ||
| GB7930421 | 1979-09-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8004585A true NL8004585A (nl) | 1981-02-18 |
Family
ID=26272594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8004585A NL8004585A (nl) | 1979-08-16 | 1980-08-13 | Werkwijze voor het bereiden van gekeratiniseerde, vaste, farmaceutische eenheidsdoseringsvormen en de aldus verkregen eenheidsdoseringsvormen. |
Country Status (8)
| Country | Link |
|---|---|
| CH (1) | CH649216A5 (enExample) |
| DE (1) | DE3029745A1 (enExample) |
| FR (1) | FR2462911A1 (enExample) |
| GB (1) | GB2057876B (enExample) |
| IE (1) | IE50107B1 (enExample) |
| IT (1) | IT1194817B (enExample) |
| NL (1) | NL8004585A (enExample) |
| SE (1) | SE8005773L (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6056122B2 (ja) * | 1980-05-21 | 1985-12-09 | 塩野義製薬株式会社 | 徐放性製剤 |
| DE3221425A1 (de) * | 1982-06-07 | 1983-12-08 | Boehringer Ingelheim KG, 6507 Ingelheim | Hydrolyseempfindlichen wirkstoff enthaltende, lagerstabile tablette |
| DE3233764C2 (de) * | 1982-09-11 | 1987-05-07 | R.P. Scherer GmbH, 6930 Eberbach | Verfahren zur Herstellung oraler Dosierungseinheiten |
| GB2132887A (en) * | 1982-11-15 | 1984-07-18 | Procter & Gamble | Enteric-coated anti-inflammatory compositions |
| US4462839A (en) * | 1983-06-16 | 1984-07-31 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| US4600645A (en) * | 1985-01-31 | 1986-07-15 | Warner-Lambert Company | Process for treating dosage forms |
| SE460947B (sv) * | 1986-08-26 | 1989-12-11 | Lejus Medical Ab | En multiple-unit-dos komposition av l-dopa |
| US4960814A (en) * | 1988-06-13 | 1990-10-02 | Eastman Kodak Company | Water-dispersible polymeric compositions |
| US5025004A (en) * | 1988-06-13 | 1991-06-18 | Eastman Kodak Company | Water-dispersible polymeric compositions |
| US5350741A (en) * | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
| US5225202A (en) * | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
| EP0584594B1 (de) | 1992-08-06 | 1998-04-01 | Gerhard Dr. Gergely | Leicht einnehmbare brausende Manteltablette |
| US5416157A (en) * | 1993-09-09 | 1995-05-16 | Eastman Chemical Company | Process for improving mechanical shear stability of acrylic enteric polymers |
| US5380790A (en) * | 1993-09-09 | 1995-01-10 | Eastman Chemical Company | Process for the preparation of acrylic polymers for pharmaceutical coatings |
| US5508276A (en) * | 1994-07-18 | 1996-04-16 | Eli Lilly And Company | Duloxetine enteric pellets |
| US5851579A (en) * | 1996-10-28 | 1998-12-22 | Eastman Chemical Company | Aqueous enteric coating compositions |
| US5910319A (en) | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
| US6139875A (en) * | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL235736A (enExample) * | 1958-02-03 | |||
| JPS517116A (en) * | 1974-06-11 | 1976-01-21 | Shinetsu Chemical Co | Choyoseihifukuyakuzaino seizohoho |
| ES438635A1 (es) * | 1974-06-24 | 1977-02-16 | Shinetsu Chemical Co | Procedimiento para el revestimiento de moldes solidos de do-sificacion. |
| JPS51123814A (en) * | 1975-04-22 | 1976-10-28 | Shin Etsu Chem Co Ltd | A process for preparing gradually releasable solid medicines |
| DE2732335C2 (de) * | 1976-07-27 | 1983-01-20 | Sandoz-Patent-GmbH, 7850 Lörrach | Tablette zur enteralen Verabreichung von Indolyloxyalkanolamin-Derivaten |
| GB1594102A (en) * | 1977-09-26 | 1981-07-30 | Sankyo Co | Ingestible coating compositions |
| DE2802114A1 (de) * | 1978-01-19 | 1979-07-26 | Sandoz Ag | Neue pharmazeutische zusammensetzung und verfahren zu deren herstellung |
-
1980
- 1980-08-04 CH CH5899/80A patent/CH649216A5/de not_active IP Right Cessation
- 1980-08-06 DE DE3029745A patent/DE3029745A1/de not_active Withdrawn
- 1980-08-13 GB GB8026316A patent/GB2057876B/en not_active Expired
- 1980-08-13 NL NL8004585A patent/NL8004585A/nl not_active Application Discontinuation
- 1980-08-14 IT IT24167/80A patent/IT1194817B/it active
- 1980-08-14 IE IE1722/80A patent/IE50107B1/en unknown
- 1980-08-15 SE SE8005773A patent/SE8005773L/ not_active Application Discontinuation
- 1980-08-18 FR FR8018042A patent/FR2462911A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| GB2057876B (en) | 1984-05-10 |
| SE8005773L (sv) | 1981-02-17 |
| DE3029745A1 (de) | 1981-03-26 |
| FR2462911A1 (fr) | 1981-02-20 |
| IE801722L (en) | 1981-02-16 |
| IE50107B1 (en) | 1986-02-19 |
| CH649216A5 (de) | 1985-05-15 |
| IT1194817B (it) | 1988-09-28 |
| IT8024167A0 (it) | 1980-08-14 |
| FR2462911B1 (enExample) | 1983-10-07 |
| GB2057876A (en) | 1981-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL8004585A (nl) | Werkwijze voor het bereiden van gekeratiniseerde, vaste, farmaceutische eenheidsdoseringsvormen en de aldus verkregen eenheidsdoseringsvormen. | |
| US5206030A (en) | Film-forming composition and use for coating pharmaceuticals, foods and the like | |
| JP3165438B2 (ja) | 水性のマルトデキストリン及びセルロースポリマーフィルムコーティング | |
| RU2528095C2 (ru) | Системы пленочного покрытия для препаратов с немедленным высвобождением, создающие усиленный барьер от влаги, и субстраты с таким покрытием | |
| JP4638046B2 (ja) | 可食性コーティング組成物 | |
| JP3237758B2 (ja) | 錠剤における陰刻を目だたせる方法 | |
| EP0035780B1 (en) | Coating compositions for enterosoluble solid dosage forms | |
| EP0072021B1 (en) | Aqueous alcoholic dispersions of ph sensitive polymers and plasticizing agents, a process for preparing the same, and a solid medicinal oral dosage form containing an enteric coating prepared by using same | |
| CN1330379C (zh) | 可食用pga涂层组合物 | |
| JPH0466450B2 (enExample) | ||
| US6485747B1 (en) | Coated active tablet(s) | |
| HUT64833A (en) | Soft capsule with coating dissoluble in intestines and method for manufacturing it | |
| CN103920159B (zh) | 涂布组合物、含药物颗粒、固体制剂和用于制备含药物颗粒的方法 | |
| JP2003514778A (ja) | 食用ｍｃｃ／ｐｇａ被覆組成物 | |
| US4931286A (en) | High gloss cellulose tablet coating | |
| Thoma et al. | Enteric coated hard gelatin capsules | |
| JPS6132289B2 (enExample) | ||
| US20060127451A1 (en) | Coating composition | |
| US3244596A (en) | Coated medicinal agents and coating compositions therefor | |
| PL202884B1 (pl) | Nietoksyczna, jadalna, powłokotwórcza kompozycja proszkowa zabezpieczająca przed działaniem soku żołądkowego, sposób sporządzania wodnego układu dyspersyjnego oraz sposób powlekania substratów | |
| WO2001032185A1 (en) | A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof | |
| BE884715A (fr) | Nouvelles compositions pharmaceutiques solides a enrobage, sous forme de doses unitaires | |
| JP3417772B2 (ja) | 無溶媒でコーティングされた固形製剤及びその後処理方法 | |
| Deshmukh et al. | Delivery of didanosine from enteric-coated, sustained-release bioadhesive formulation | |
| JPS6299322A (ja) | 硬カプセル剤の新しい剤形 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |